A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

NCT05394012 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: RQ3013
BIOLOGICAL: Comirnaty

Sponsor

Walvax Biotechnology Co., Ltd.

Collaborators

[object Object]